Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
DGAP-News: Evotec SE / Key word(s): Miscellaneous
19.04.2021 / 08:31
The issuer is solely responsible for the content of this announcement.
EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801
KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC
EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC )
EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES
Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC
EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC )
EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES
HAMBURG, GERMANY / ACCESSWIRE / April 19, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited ( Kazia , ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec s oncology project EVT801.
Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 – Health Technology Net digitalfacility.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitalfacility.com Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
2021-04-19 / 08:31
The issuer is solely responsible for the content of this announcement.
= . EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801 . KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC . EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC ) . EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES